GDTC Short Volume

CytoMed Therapeutics Limited (GDTC) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $14.2M, listed on NASDAQ, employing roughly 43 people, carrying a beta of -0.17 to the broader market. CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. Led by Chee Kong Choo, public since 2023-04-14.

Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.

Latest Date
2026-06-01
Short Volume
38
Total Volume
1.4K
Short %
2.65%
30-Day Avg Short %
35.13%

Showing 30 days of FINRA short volume data for CytoMed Therapeutics Limited.

Learn how short volume is reported and how to read the data →

Frequently asked GDTC short volume questions

What is the daily GDTC short volume?
As of Jun 1, 2026, CytoMed Therapeutics Limited (GDTC) short volume is 38 shares against 1.4K total reported volume, or 2.65% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
How is GDTC short volume reported?
FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
What does GDTC short volume tell options traders?
Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.